CagriSema bone density data at ObesityWeek point to a calcitonin receptor role
Novo Nordisk showed rat, volunteer and post hoc REDEFINE 1 data suggesting amylin and calcitonin receptor drugs may limit bone loss during weight loss. The company calls the work hypothesis generating, and fractures were not studied.
What's new
Novo Nordisk presented rat, volunteer and post hoc REDEFINE 1 data at ObesityWeek 2026 suggesting that activating amylin and calcitonin receptors may limit bone loss during weight loss.
Why it matters
Large weight loss can thin bone and raise fracture risk, a concern for older women, and CagriSema is under FDA review for weight management.
What's next
Novo says longer clinical studies are needed to test bone outcomes, and an FDA decision on CagriSema is expected in the fourth quarter of 2026.
CagriSema bone density results from a post hoc look at the Phase 3 REDEFINE 1 trial were part of new Novo Nordisk data shown at ObesityWeek 2026 on 16 November. The company said drugs that switch on both the amylin and calcitonin receptors showed early signs of limiting bone loss during weight loss, in rats and in small human biomarker studies. Novo stressed that these analyses only generate hypotheses and that no trial has yet tested fracture risk.
Why bone loss during weight loss matters
Large weight loss changes the load the skeleton carries. Bones bear less weight, and the body responds by removing some of the mineral it no longer seems to need. Novo said in its release that this happens after diet, after surgery and with medicines, and that with extensive loss it can weaken bone over time and raise the chance of fractures. The worry is sharper for older women, whose bone mass already falls after menopause as estrogen drops. Obesity drugs now produce weight loss that once needed an operation, so doctors want to know whether the same drugs also thin bone. That question has followed the GLP 1 class for years, and amylin based drugs now face it as they near possible approval.
Novo builds its case on receptor biology. Cagrilintide, one half of CagriSema, acts on both the amylin receptor and the calcitonin receptor. Zenagamtide, the molecule formerly called amycretin, adds activity at the GLP 1 receptor on top of those two. The calcitonin receptor sits on osteoclasts, the cells that break bone down, and activating it can slow their work, the company said. To test whether that receptor explains any bone effect, Novo also studied NN1213, an experimental drug that reaches the amylin receptor alone. All four compounds, CagriSema, cagrilintide, zenagamtide and NN1213, are investigational. None is approved in the United States, and Novo says their safety and efficacy have not been established for any use.
Calcitonin receptor signal in rats and volunteers
The animal work used female rats whose ovaries had been removed, a standard model of the bone loss that follows menopause. Over eight weeks, cagrilintide and CagriSema reduced the loss of trabecular bone, the spongy inner bone that changes fastest, and protected its fine structure, according to Novo. The comparison groups were untreated animals and animals held to the same weight by diet. Measured in the femur against weight matched controls, cagrilintide left 43% more trabecular bone volume and CagriSema 40% more, and both gaps were statistically significant. Zenagamtide came in 30% higher and semaglutide 11% higher, but neither difference reached significance. NN1213 was left out of this model, so the rat data alone cannot separate the roles of the two receptors.
Measured in the femur against weight matched controls, cagrilintide left 43% more trabecular bone volume and CagriSema 40% more, and both gaps were statistically significant.
Small studies in healthy volunteers tried to fill that gap. In them, cagrilintide and zenagamtide lowered CTX I, a blood marker that rises when bone is being broken down. NN1213, which reaches the amylin receptor but not the calcitonin receptor, did not show the same effect, Novo reported. The company reads this contrast as a sign that the calcitonin receptor drives the bone signal. That reading is plausible, but it rests on a blood marker rather than on bone scans or fractures, and the release gives neither the number of volunteers nor the size of the CTX I changes. Other amylin drugs in development, including the one tested in the petrelintide weight loss trial, will likely face the same bone questions as they advance.
CagriSema bone density in REDEFINE 1
The human data with the most weight come from REDEFINE 1, the 68 week Phase 3 trial that compared once weekly CagriSema with its two parts and with placebo in 3,417 adults with obesity or overweight and at least one related condition, none with type 2 diabetes. A substudy of 252 participants had DXA scans, the standard X ray test for bone mineral density, and the analysis focused on 154 people on CagriSema and 55 on placebo. In the CagriSema group, bone mineral density fell, as expected with large weight loss, but remained inside the usual range for people of the same age and sex at week 68, Novo said. The trial is registered as NCT05567796 on ClinicalTrials.gov. The release does not state the size of that fall or give a direct comparison with the placebo group.
A larger set of REDEFINE 1 participants also gave blood for bone markers and for a preselected panel of 23 proteins from baseline to week 68. The rise in CTX I with cagrilintide alone was similar to placebo. With CagriSema it was modestly higher than with semaglutide alone, even though CagriSema produced much more weight loss. P1NP, a marker of new bone formation, sat above baseline by week 68. Proteins linked to bone formation and mineralization rose with cagrilintide and CagriSema but not with semaglutide alone, and those changes held after adjusting for weight loss, the company said. The table below lists the figures Novo released, with the comparison behind each one, since several results are described only in words.
| Analysis | Comparison | Reported result |
|---|---|---|
| Rat menopause model, femur | Cagrilintide vs weight matched controls | 43% more trabecular bone volume, significant |
| Rat menopause model, femur | CagriSema vs weight matched controls | 40% more, significant |
| Rat menopause model, femur | Zenagamtide vs weight matched controls | 30% more, not significant |
| Rat menopause model, femur | Semaglutide vs weight matched controls | 11% more, not significant |
| REDEFINE 1 DXA substudy | 154 on CagriSema, 55 on placebo | Density fell but stayed in the normal range at week 68 |
| REDEFINE 1 blood panel | 23 preselected proteins | Bone formation proteins rose with cagrilintide and CagriSema |
Limits of the data and the FDA decision ahead
Several limits apply. The REDEFINE 1 bone work is a post hoc analysis, which means the questions were asked after the trial was designed and run, and Novo itself calls such analyses hypothesis generating. The trial was not built to measure fractures, and the company says that answering it would take longer follow up. The rat model copies one cause of bone loss, not the mix seen in people with obesity. The data were presented at the meeting by Novo researcher Marco Ponzetti rather than published in a peer reviewed paper, and Novo funded all of the work. Chief scientific officer Martin Holst Lange said that "further clinical research is needed to establish if these findings translate into long-term bone health outcomes."
Safety data from REDEFINE 1 set the context for any bone claim. Discontinuation because of adverse events was 5.9% with CagriSema and 3.7% with placebo, and gastrointestinal events reached 79.6% against 39.9%, mostly mild to moderate and short lived, according to Novo. Novo filed a new drug application for CagriSema in weight management with the FDA in December 2025 and expects a decision in the fourth quarter of 2026. CagriSema bone density findings will not decide that review, but they may shape how prescribers weigh the drug for older patients. Earlier coverage of the CagriSema ObesityWeek slate listed the data Novo planned to show. Further readouts sit on the Peptide Zone trials desk.
Conclusion
The new CagriSema bone density data suggest, but do not prove, that drugs acting on the calcitonin receptor may soften the bone loss that comes with large weight loss. The clearest numbers come from rats, and the human results rest on post hoc analyses and blood markers from a company funded program. Fracture outcomes remain untested. The FDA decision on CagriSema, expected this quarter, will turn on efficacy and safety, while the bone question will need a trial designed to answer it.